Vita Life Sciences Management

Management criteria checks 3/4

Vita Life Sciences' CEO is Andrew O'Keefe, appointed in Jan 2017, has a tenure of 7.42 years. total yearly compensation is A$886.73K, comprised of 49.8% salary and 50.2% bonuses, including company stock and options. directly owns 1.05% of the company’s shares, worth A$1.40M. The average tenure of the management team and the board of directors is 7.4 years and 4.6 years respectively.

Key information

Andrew O'Keefe

Chief executive officer

AU$886.7k

Total compensation

CEO salary percentage	49.8%
CEO tenure	7.4yrs
CEO ownership	1.0%
Management average tenure	7.4yrs
Board average tenure	4.6yrs

Recent management updates

Recent updates

CEO Compensation Analysis

How has Andrew O'Keefe's remuneration changed compared to Vita Life Sciences's earnings?
Date	Total Compensation	Salary	Company Earnings
Dec 31 2023	AU$887k	AU$442k	AU$9m
Sep 30 2023	n/a	n/a	AU$8m
Jun 30 2023	n/a	n/a	AU$7m
Mar 31 2023	n/a	n/a	AU$7m
Dec 31 2022	AU$984k	AU$438k	AU$7m
Sep 30 2022	n/a	n/a	AU$8m
Jun 30 2022	n/a	n/a	AU$8m
Mar 31 2022	n/a	n/a	AU$8m
Dec 31 2021	AU$653k	AU$442k	AU$8m
Sep 30 2021	n/a	n/a	AU$8m
Jun 30 2021	n/a	n/a	AU$7m
Mar 31 2021	n/a	n/a	AU$6m
Dec 31 2020	AU$510k	AU$440k	AU$6m
Sep 30 2020	n/a	n/a	AU$6m
Jun 30 2020	n/a	n/a	AU$5m
Mar 31 2020	n/a	n/a	AU$4m
Dec 31 2019	AU$535k	AU$442k	AU$3m
Sep 30 2019	n/a	n/a	AU$2m
Jun 30 2019	n/a	n/a	AU$2m
Mar 31 2019	n/a	n/a	AU$2m
Dec 31 2018	AU$424k	AU$421k	AU$2m
Sep 30 2018	n/a	n/a	AU$3m
Jun 30 2018	n/a	n/a	AU$4m
Mar 31 2018	n/a	n/a	AU$3m
Dec 31 2017	AU$445k	AU$408k	AU$3m

Compensation vs Market: Andrew's total compensation ($USD589.03K) is above average for companies of similar size in the Australian market ($USD297.74K).

Compensation vs Earnings: Andrew's compensation has been consistent with company performance over the past year.

CEO

Andrew O'Keefe

7.4yrs

Tenure

AU$886,732

Compensation

Mr. Andrew W. O'Keefe has been Managing Director and Director of Vita Life Sciences Limited since January 1, 2017. Mr. O'Keefe served as Acting Managing Director of Vita Life Sciences Limited since October...

Leadership Team

Name	Position	Tenure	Compensation	Ownership
Andrew O'Keefe	MD & Director	7.4yrs	AU$886.73k	1.05% A$ 1.4m
Chin Khoo	CFO & Company Secretary	7.1yrs	AU$365.80k	0.99% A$ 1.3m
Melissa Pereira	Group Marketing Manager	7.4yrs	AU$175.02k	0.31% A$ 416.5k
Shaun Rutherford	Chief Executive Officer of Australia	no data	AU$521.94k	0.93% A$ 1.2m
June Lau	General Manager of Operations & Business Support	no data	no data	no data
Alexandra Ward	Technical & NPD Manager	no data	no data	no data

7.4yrs

Average Tenure

Experienced Management: VLS's management team is seasoned and experienced (7.4 years average tenure).

Board Members

Name	Position	Tenure	Compensation	Ownership
Andrew O'Keefe	MD & Director	7.4yrs	AU$886.73k	1.05% A$ 1.4m
Henry Townsing	Non-Executive Chairman	12.5yrs	AU$136.90k	0.77% A$ 1.0m
Peter Osborne	Independent Non-Executive Director	less than a year	AU$16.67k	0.045% A$ 60.1k
Jack Teoh	Non-Executive Director	1.8yrs	AU$37.21k	no data

4.6yrs

Average Tenure

Experienced Board: VLS's board of directors are considered experienced (4.6 years average tenure).

Vita Life Sciences Management

Management criteria checks 3/4

Key information

Recent management updates

Non-Executive Chairman recently sold AU$654k worth of stock

MD & Director recently sold AU$1.9m worth of stock

Vita Life Sciences Limited, Annual General Meeting, May 15, 2024

Less than half of directors are independent

Less than half of directors are independent

Less than half of directors are independent

Recent updates

Non-Executive Chairman recently sold AU$654k worth of stock

New minor risk - Insider selling

MD & Director recently sold AU$1.9m worth of stock

Upcoming dividend of AU$0.06 per share

Vita Life Sciences Limited, Annual General Meeting, May 15, 2024

Final dividend increased to AU$0.06

Full year 2023 earnings released: EPS: AU$0.17 (vs AU$0.13 in FY 2022)

Less than half of directors are independent

Vita Life Sciences Limited Provides Earnings Guidance for the Full Year Ending December 31, 2023

Less than half of directors are independent

Upcoming dividend of AU$0.03 per share at 3.7% yield

Less than half of directors are independent

Vita Life Sciences Limited Announces Interim Dividend for the Six Months Ended June 30, 2023, 6 October 2023

Vita Life Sciences Limited Appoints Peter Osborne as an Independent Non-Executive Director

No independent directors

No independent directors

No independent directors

No independent directors

Full year 2022 earnings released: EPS: AU$0.13 (vs AU$0.16 in FY 2021)

Upcoming dividend of AU$0.033 per share at 3.9% yield

No independent directors

Full year 2022 earnings released: EPS: AU$0.13 (vs AU$0.16 in FY 2021)

No independent directors

No independent directors

No independent directors

No independent directors

Vita Life Sciences Provides Earnings Guidance for the Full Year Ending 31 December 2022

No independent directors

Less than half of directors are independent

Vita Life Sciences Limited Announces Board Changes, Effective 30 September 2022

Upcoming dividend of AU$0.028 per share

Vita Life Sciences Limited Declares Fully Franked Interim Dividend for the Six Months Ended June 30, 2022, Payable on 7 October 2022

First half 2022 earnings released: EPS: AU$0.069 (vs AU$0.07 in 1H 2021)

Less than half of directors are independent

Less than half of directors are independent

Vita Life Sciences Limited Provides Earnings Guidance for the Half Year Ending June 30, 2022

Less than half of directors are independent

Upcoming dividend of AU$0.03 per share

Investor sentiment improved over the past week

Full year 2021 earnings: Revenues and EPS in line with analyst expectations

Less than half of directors are independent

Vita Life Sciences Limited Announces Dividend for Six Months Ended December 31, 2021, Payable on April 7, 2022

Less than half of directors are independent

Less than half of directors are independent

Investor sentiment improved over the past week

Investor sentiment improved over the past week

Less than half of directors are independent

Upcoming dividend of AU$0.028 per share

First half 2021 earnings released: EPS AU$0.07 (vs AU$0.058 in 1H 2020)

Less than half of directors are independent

Less than half of directors are independent

Vita Life Sciences Limited Provides Earnings Guidance for the Half Year Ending June 30, 2021

Upcoming Dividend of AU$0.015 Per Share

Earnings released

CEO Compensation Analysis

CEO

Tenure

Compensation

Leadership Team

Average Tenure

Board Members

Average Tenure